Payment overview · 2025
General Payments
$667.69
39 reported records · 13 companies
Healthcare provider profile · identity verified
Dawn Michelle Barlow, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LIVINGSTON, TN · NPI 1174644538
Verified facts
What the public records show
CMS Open Payments records show Dawn Michelle Barlow, MD received $667.69 in general payments during 2025 across 39 reported records.
Novo Nordisk Inc accounted for 47.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Kerendia, Mounjaro, Ozempic, Rybelsus, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Kerendia by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 161 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Paxlovid by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $315.05 | 47.2% | 18 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $57.12 | 8.6% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $46.35 | 6.9% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $43.89 | 6.6% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $35.95 | 5.4% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $33.14 | 5.0% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $28.01 | 4.2% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $23.00 | 3.4% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $22.83 | 3.4% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $19.35 | 2.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.12 | 2.4% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14.72 | 2.2% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $12.16 | 1.8% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $667.69 | 39 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $168.84 | 9 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $121.97 | 6 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $62.84 | 4 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $57.12 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $43.89 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $43.89 | 3 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $35.95 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $35.95 | 2 | 2025 |
Source payment records
|
|||||
| TRUMENBA Normalized: trumenba |
Biological | PFIZER INC. | $35.95 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $33.14 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $31.83 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $23.00 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $22.83 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $19.35 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $16.12 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $14.96 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $14.72 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.52 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.52 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $12.16 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 122 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 58 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 161 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
33 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
122 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
58 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
161 | 33 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
116 | 30 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
25 | 25 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 555 | 140 |
| Atorvastatin Calcium | Atorvastatin Calcium | 505 | 145 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 467 | 136 |
| Gabapentin | Gabapentin | 411 | 82 |
| Omeprazole | Omeprazole | 376 | 111 |
| Pantoprazole Sodium | Pantoprazole Sodium | 367 | 115 |
| Losartan Potassium | Losartan Potassium | 335 | 108 |
| Lisinopril | Lisinopril | 332 | 110 |
| Metformin Hcl | Metformin Hcl | 273 | 75 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 261 | 32 |
| Trazodone Hcl | Trazodone Hcl | 261 | 80 |
| Furosemide | Furosemide | 257 | 93 |
| Amlodipine Besylate | Amlodipine Besylate | 252 | 75 |
| Metoprolol Succinate | Metoprolol Succinate | 252 | 71 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 248 | 56 |
| Metoprolol Tartrate | Metoprolol Tartrate | 246 | 71 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 233 | 73 |
| Duloxetine Hcl | Duloxetine Hcl | 214 | 64 |
| Potassium Chloride | Potassium Chloride | 210 | 70 |
| Meloxicam | Meloxicam | 185 | 68 |
| Escitalopram Oxalate | Escitalopram Oxalate | 178 | 65 |
| Montelukast Sodium | Montelukast Sodium | 171 | 49 |
| Oxycodone Hcl | Oxycodone Hcl | 170 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 166 | 76 |
| Ozempic | Semaglutide | 161 | 33 |
| Sertraline Hcl | Sertraline Hcl | 153 | 36 |
| Tramadol Hcl | Tramadol Hcl | 134 | 33 |
| Alprazolam | Alprazolam | 133 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 128 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 127 | 41 |
| Allopurinol | Allopurinol | 124 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 124 | 39 |
| Jardiance | Empagliflozin | 122 | 27 |
| Alendronate Sodium | Alendronate Sodium | 121 | 51 |
| Eliquis | Apixaban | 116 | 30 |
| Prednisone | Prednisone | 116 | 76 |
| Clonazepam | Clonazepam | 111 | 13 |
| Atenolol | Atenolol | 109 | 33 |
| Simvastatin | Simvastatin | 102 | 30 |
| Diclofenac Sodium | Diclofenac Sodium | 99 | 49 |
| Zolpidem Tartrate | Zolpidem Tartrate | 99 | 13 |
| Lorazepam | Lorazepam | 98 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 95 | 82 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 95 | 30 |
| Citalopram Hbr | Citalopram Hydrobromide | 92 | 26 |
| Spironolactone | Spironolactone | 92 | 33 |
| Metformin Hcl Er | Metformin Hcl | 90 | 35 |
| Pregabalin | Pregabalin | 86 | 22 |
| Amitriptyline Hcl | Amitriptyline Hcl | 79 | 27 |
| Carvedilol | Carvedilol | 79 | 24 |
| Ondansetron Hcl | Ondansetron Hcl | 79 | 36 |
| Donepezil Hcl | Donepezil Hcl | 78 | 23 |
| Famotidine | Famotidine | 78 | 35 |
| Fluconazole | Fluconazole | 73 | 45 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 66 | 50 |
| Nystatin | Nystatin | 65 | 36 |
| Fluoxetine Hcl | Fluoxetine Hcl | 64 | 18 |
| Warfarin Sodium | Warfarin Sodium | 63 | suppressed |
| Repatha Sureclick | Evolocumab | 61 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 59 | 19 |
| Testosterone Cypionate | Testosterone Cypionate | 59 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 59 | 15 |
| Mounjaro | Tirzepatide | 58 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 55 | 50 |
| Buspirone Hcl | Buspirone Hcl | 54 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 54 | 14 |
| Azithromycin | Azithromycin | 53 | 45 |
| Morphine Sulfate Er | Morphine Sulfate | 53 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 52 | 21 |
| Methylprednisolone | Methylprednisolone | 52 | 47 |
| Nitroglycerin | Nitroglycerin | 51 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 50 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 50 | 31 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 49 | 31 |
| Lidocaine | Lidocaine | 48 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 47 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 47 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 47 | 41 |
| Chlorthalidone | Chlorthalidone | 46 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 46 | suppressed |
| Levetiracetam | Levetiracetam | 45 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 45 | 14 |
| Xarelto | Rivaroxaban | 45 | 11 |
| Ondansetron Odt | Ondansetron | 44 | 26 |
| Clonidine Hcl | Clonidine Hcl | 43 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 43 | 14 |
| Lovastatin | Lovastatin | 42 | 13 |
| Ketoconazole | Ketoconazole | 40 | 20 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 39 | suppressed |
| Mupirocin | Mupirocin | 39 | 32 |
| Mirtazapine | Mirtazapine | 38 | 17 |
| Nifedipine Er | Nifedipine | 37 | 11 |
| Propranolol Hcl | Propranolol Hcl | 36 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 36 | 11 |
| Farxiga | Dapagliflozin Propanediol | 35 | suppressed |
| Glipizide | Glipizide | 35 | 11 |
| Lamotrigine | Lamotrigine | 35 | suppressed |
| Methocarbamol | Methocarbamol | 35 | suppressed |
| Tradjenta | Linagliptin | 35 | suppressed |
| Cefdinir | Cefdinir | 34 | 29 |
| Linzess | Linaclotide | 34 | suppressed |
| Topiramate | Topiramate | 34 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 33 | suppressed |
| Synthroid | Levothyroxine Sodium | 33 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Baclofen | Baclofen | 31 | suppressed |
| Folic Acid | Folic Acid | 30 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | suppressed |
| Ezetimibe | Ezetimibe | 29 | suppressed |
| Glimepiride | Glimepiride | 29 | suppressed |
| Levofloxacin | Levofloxacin | 28 | 22 |
| Meclizine Hcl | Meclizine Hcl | 28 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Novolog Flexpen | Insulin Aspart | 25 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 25 | 25 |
| Pioglitazone Hcl | Pioglitazone Hcl | 25 | suppressed |
| Sucralfate | Sucralfate | 25 | 15 |
| Diazepam | Diazepam | 24 | suppressed |
| Finasteride | Finasteride | 24 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Trulicity | Dulaglutide | 24 | suppressed |
| Estradiol | Estradiol | 23 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 23 | suppressed |
| Temazepam | Temazepam | 23 | suppressed |
| Aripiprazole | Aripiprazole | 22 | suppressed |
| Valsartan | Valsartan | 22 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 21 | 16 |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Celecoxib | Celecoxib | 20 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 20 | suppressed |
| Xifaxan | Rifaximin | 20 | suppressed |
| Norethindron-Ethinyl Estradiol | Norethindrone Ac/Eth Estradiol | 19 | suppressed |
| Olanzapine | Olanzapine | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Indapamide | Indapamide | 18 | suppressed |
| Levemir Flexpen | Insulin Detemir | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 17 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 17 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 16 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Levoxyl | Levothyroxine Sodium | 15 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Brilinta | Ticagrelor | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Oxycontin | Oxycodone Hcl | 13 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 12 | suppressed |
| Dexamethasone | Dexamethasone | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Kerendia | Finerenone | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | 11 |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Xtampza Er | Oxycodone Myristate | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Eletriptan Hbr | Eletriptan Hydrobromide | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $667.69 · 39 records | Novo Nordisk Inc | CAPLYTA, COMIRNATY, Cologuard Collection Kit, JARDIANCE, Kerendia, Korlym, MOUNJARO, OTEZLA, Ozempic, PENBRAYA, PREVNAR 20, REPATHA, REXULTI, Rybelsus, TRUMENBA, VOQUEZNA, VRAYLAR, Wegovy, XIFAXAN, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error